Startups, Venture

They got bounced out of Alexion. Now David Hallal and Vikas Sinha are back with $150M and a focus on cell and gene therapies

David Hallal and Vikas Sinha got bounced out of their jobs as CEO and CFO of Alexion the hard way more than 2 years ago, dismissed after failing to maintain the confidence of the board as a probe into the company’s sketchy sales and billing practices triggered a top-to-bottom overhaul of the management and the operations — with a move to Boston.

But it didn’t end their biotech careers. Not by a long shot.

“I spent more than a decade at Alexion building one of the most successful biotechs in the world,” says Hallal. And the best way to handle the situation at the end, the persistently upbeat biotech exec says, was to channel the emotion into new endeavors while “looking forward.”


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->